Benzylisoquinoline compound, preparation method and application

A technology of benzylisoquinolines and compounds, applied in the fields of active ingredients of heterocyclic compounds, organic chemistry, drug combination, etc., can solve severe allergies and other problems, and achieve the effect of short duration of muscle relaxation and rapid disappearance of muscle relaxation

Inactive Publication Date: 2018-07-06
SICHUAN DAOZHEN TECH CO LTD
0 Cites 11 Cited by

AI-Extracted Technical Summary

Problems solved by technology

[0005] It can be seen that the current muscle relaxation drug reversal technology requires the external administration of a large number of molecules that are not related to the therapeutic effect to release the mus...
View more

Abstract

The structural formula is shown in the description, wherein Ar1, Ar2, Ar3 and Ar4 are non-substituted or substituted aryl groups; R is H or C1-5 alkyl group; R1, R2, R3 and R4 can be independent H orC1-5 alkyl groups; in addition, R1 and R2 can form C2-5 ene groups commonly, and R3 and R4 can form C2-5 ene groups commonly; B1 is C1-9 substituted or non-substituted, saturated or unsaturated alkylene groups, and the skeleton of B1 can contain heteroatoms such as O; B2 is C1-8 substituted or non-substituted, saturated or unsaturated alkylene groups, and the skeleton of B2 can contain heteroatomssuch as O; X is O or CH2 or NR5, wherein R5 is H or C1-5 alkyl groups; Y is O or CH2 or C(O)O; S is pharmaceutically-acceptable anions such as bromide ions, sulfonate ions. A stereoisomer with a structure shown in a formula (I), a stereoisomer mixture or pharmaceutically-acceptable salts and a pharmaceutical composition formed by the pharmaceutically-acceptable salts and pharmaceutically-acceptable carriers can generate a neuromuscular junction blocking effect and can be applied in the field of preparation of medicines for muscular relaxation.

Application Domain

Organic chemistryMuscular disorder +3

Technology Topic

Block effectBromide ions +6

Image

  • Benzylisoquinoline compound, preparation method and application
  • Benzylisoquinoline compound, preparation method and application
  • Benzylisoquinoline compound, preparation method and application

Examples

  • Experimental program(4)

Example Embodiment

[0042] Example 1
[0043]
[0044] Combine 715 mg of Laudansine (CAS:1699-51-0) and 334 mg of methyl 3-bromopropionate in 30 mL of acetonitrile, stir at 55°C for 24 hours, evaporate the acetonitrile under reduced pressure, and perform column chromatography (dichloromethane/methanol =10/1) to obtain 590mg of N-methyl-N-propionic acid methyl laudansine quaternary ammonium salt, add 20mL of 2N sodium hydroxide aqueous solution, hydrolyze at room temperature for 2 hours, adjust the Ph value to 9 with hydrobromic acid aqueous solution, reduce The solvent was evaporated to dryness, and the crude product was subjected to column chromatography (dichloromethane/methanol=10/1) to obtain 280 mg of N-methyl-N-propionyllaudansin quaternary ammonium bromide sodium salt, which is fragment a.
[0045] Combine 715 mg of Laudansine (CAS:1699-51-0) and 334 mg of 5-bromopentanol in 30 mL of acetonitrile, stir at 55°C for 24 hours, evaporate the acetonitrile under reduced pressure, and perform column chromatography (dichloromethane/methanol=10 /1) To obtain 410 mg of N-methyl-N-hydroxypentyllaudanine bromide quaternary ammonium salt, add 20 mL of dichloromethane, 101 mg of chloromethyl chloroformate and 125 mg of pyridine, stir at room temperature for 5 hours, and obtain by column chromatography 232 mg of N-methyl-N-chloromethyl pentyllaudanine carbonate quaternary ammonium salt, which is fragment b.
[0046] Dissolve 232 mg of fragment b and 200 mg of fragment a in 20 mL DMF, react at room temperature for 36 hours, evaporate DMF under reduced pressure, and obtain 118 mg of the target compound of formula (I) by column chromatography (dichloromethane/methanol=10/1).
[0047] HNMR(d-DMSO): 1.23~1.29(2H,m), 1.59~1.72(4H,m), 2.67(2H,t,J=8Hz), 2.91~3.65(46H,m),4.21(2H,t) ,J=8Hz), 4.89~4.95(2H,m), 5.77(2H,s), 6.08~6.81(10H,m).

Example Embodiment

[0048] Example 2
[0049]
[0050] According to the method described in Example 1, using (S)-Labdanine (CAS: 2688-77-9) as the starting material, the S, S isomer of the compound of formula (I) can be obtained.
[0051] HNMR(d-DMSO): 1.21~1.27(2H,m), 1.56~1.73(4H,m), 2.72(2H,t,J=8Hz), 2.88~3.68(46H,m), 4.19(2H,t) ,J=8Hz), 4.91~4.97(2H,m), 5.87(2H,s), 6.05~6.89(10H,m).

Example Embodiment

[0052] Example 3
[0053] Some of the compounds described in the examples were subjected to in vitro decomposition experiments of rabbit plasma. Add 200μg drug-containing DMSO solution (10μL) to 4mL rabbit plasma to make the plasma drug concentration 50μg/mL. After mixing, incubate at 37℃ immediately, and take 200μL drug-containing plasma at 2min, 5min, 10min, and 20min. , Add 600μL methanol, take the supernatant after centrifugation, determine the drug content by HPLC, the specific measurement conditions are: 4.6X50mm, 5μm C18 column, 0.04% trifluoroacetic acid aqueous solution as mobile phase A, 0.02% trifluoroacetic acid acetonitrile solution B mobile phase, flow rate 1.5mL/min, column temperature 45°C, gradient elution (B: 10%/2.5min→80%/1.5min→10%/2min), diode array detector. The measured drug concentration is compared with the initial drug concentration when the sample is injected, and the remaining percentage of the drug at each time point is calculated. The results show that most of the compounds in the examples can be completely decomposed within 5 minutes in plasma (Table 1). After the above experimental plasma was replaced with 20% rabbit liver homogenate, the decomposition was faster. The specific decomposition situation is shown in Table 2.
[0054] Table 1 Decomposition of drugs in rabbit plasma
[0055]
[0056] -: The prototype drug cannot be detected.
[0057] Table 2 Decomposition of drugs in rabbit liver homogenate
[0058]
[0059] -: The prototype drug cannot be detected.

PUM

no PUM

Description & Claims & Application Information

We can also present the details of the Description, Claims and Application information to help users get a comprehensive understanding of the technical details of the patent, such as background art, summary of invention, brief description of drawings, description of embodiments, and other original content. On the other hand, users can also determine the specific scope of protection of the technology through the list of claims; as well as understand the changes in the life cycle of the technology with the presentation of the patent timeline. Login to view more.
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products